Contributor Since 2009
OncoSil Medical (ASX: OSL) chairman Martin Rogers has acquired 662,000 shares of the company on the market.
He paid a total of $79,84920, or an average of about $0.12, for the shares. This brings his total shareholding up to 9,907,384 shares.
Rogers also holds 19 million options.
The company is developing OncoSil™ as a localised, implantable nuclear medicine device for the treatment of pancreatic cancer. It emits radiation directly into the pancreatic tumour and the pain conducting nerves surrounding it.
Radiation therapy, such as that provided by OncoSil™, has been proven over many years to kill tumour cells. OncoSil™ delivers radiation therapy locally for up to three months (P32 half-life of 14.3 days). There may also be potential use for OncoSil™ in other cancer indications.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.